Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IP Group PLC Capital/Financing Update 2020

May 26, 2020

4852_cap_2020-05-26_dfb46769-a1d0-4a79-9eab-a8ef520302b3.html

Capital/Financing Update

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

RNS Number : 8390N

IP Group PLC

26 May 2020

FOR RELEASE ON # 26 May 2020

IP Group plc - Portfolio company Oxford Nanopore Technologies announces £48.4m of additional funding

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that its portfolio company Oxford Nanopore Technologies Limited ("Oxford Nanopore"), has announced that it has raised an additional £48.4 million of new capital to support ongoing innovation and rapid growth. Oxford Nanopore is the company behind the only real-time DNA/RNA sequencer that can sequence any read length and is fully scalable from smaller portable formats to larger devices for population-scale sequencing.

The funding came from both new and existing shareholders in EMEA, US and Asia and adds to the £29.3 million of capital raised that was announced on 2 January.

Following completion of the funding round, IP Group holds an undiluted beneficial stake of 15.9%. The directors expect that the Group's holding will be valued at £257.7 million, a reduction of £6.1 million, although will review the carrying value of Oxford Nanopore, as usual, as part of the Group's Half-Yearly Results to 30 June 2020 in light of this funding round and all other relevant information.

Oxford Nanopore's sequencing devices are being used in scientific research worldwide, and increasingly in regulated environments such as healthcare and food safety. The technology is being used extensively for epidemiology and research purposes in the current COVID-19 pandemic. The company also announced last week that it has a new category of COVID-19 test, LamPORE, in advanced development.

For more information, please contact:

IP Group plc www.ipgroupplc.com
Greg Smith, Chief Financial Officer

Liz Vaughan-Adams, Communications
+44 (0) 20 7444 0050

+44 (0) 20 7444 0062/+44 (0) 7979 853802
Charlotte Street Partners
David Gaffney +44 (0) 7854 609998
Andrew Wilson +44 (0) 7810 636995

Notes for editors

About IP Group

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

For more information, please visit our website at www.ipgroupplc.com.

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

NRAEADSSAEEEEAA